Dr. Reddy’s Laboratories Limited (ADR) (RDY), Abbott Laboratories (ABT): Positive Outlook for the Generic Version of Depakote ER

According to the company’s investor presentation in June, the company experienced a 26% year-over-year growth in revenues exceeding $2 billion in the 2013 fiscal year. The revenues increased significantly in all the regions except Europe. The earnings before interest, taxes, depreciation and amortization (EBITDA) growth was 36% year-over-year. The company’s current and non-current liabilities decreased by 0.3%.

Game plans of the competitors
According to a company press release, Mylan Inc. (NASDAQ:MYL) also launched the generic version of Depakote ER back in 2011. Recently, Mylan Inc. (NASDAQ:MYL) launched generic versions of two new drugs. In mid-July it launched northindrone tablets, which is the generic version of Watson Laboratories’ Nor-Q.D. tablets, and fenofibric acid delayed capsules, which is the first generic version of Abbot Laboratries’ Trilipix capsules. Northindrone tablets had U.S. sales of approximately $39 million for the 12 months ending on March 31, while fenofibric acid delayed capsules had sales of approximately $553.6 million for the same period and market.

Bottom line
After the launch of a new generic drug to meet an increasing demand in the U.S. market, Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) is expected to register strong returns in upcoming quarters. The company’s financial performance is also getting stronger, assuring higher returns for investors. It also pays one of the highest dividends in the industry, encouraging more investors to invest in its stock.

The article Positive Outlook for the Generic Version of Depakote ER originally appeared on Fool.com and is written by usman iftikhar.

usman iftikhar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.